Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy

Tharimmune, a biotechnology company focused on developing innovative treatments, experienced a significant increase in its stock value, surging by 30%. This notable rise in share price comes as a result of the company successfully raising $540 million in capital. The funds will be allocated towards implementing a strategic initiative aimed at building a robust treasury for the Canton Coin, a digital currency project that the company aims to develop. Investors are optimistic about the potential of the Canton Coin strategy to enhance Tharimmune's financial standing and contribute to its long-term growth and success. source: https://www.coindesk.com/business/2025/11/03/tharimmune-stock-g-raises-usd540m-to-build-canton-coin-treasury-strategy